Of all the home-based care verticals, hospice consistently commands the highest EBITDA multiples at acquisition. In 2026, quality hospice agencies are transacting at 5.0× to 9.0× EBITDA — and exceptional platforms with strong payor mix, low churn, and geographic density regularly exceed that range. Yet the vast majority of hospice owners we speak with significantly underestimate what their business is worth.
This guide explains exactly how hospice agency valuations are determined, what drives multiples to the high end of the range, and where the market stands today.
Hospice is one of the most attractive acquisition targets in healthcare M&A for several converging reasons:
1. Medicare as the dominant payer. Roughly 87% of hospice days are paid by Medicare — federal, reliable, and not subject to the Medicaid rate risk that weighs on non-skilled home care. Institutional buyers model Medicare revenue as highly predictable, which reduces their discount rate and supports higher multiples.
2. Recurring, non-episodic revenue. Unlike home health, which is episodic by nature (START → CERT → discharge), hospice patients remain enrolled for months or years. Average length of stay in a well-run hospice is 90–180 days, with a meaningful percentage of patients enrolled for over 6 months. This creates predictable census, predictable revenue, and predictable cash flow.
3. Demographic tailwinds. The U.S. has approximately 11,000 Baby Boomers turning 65 every day. Hospice utilization rates have grown every consecutive year for the past decade. Buyers are not just paying for today’s cash flow — they are buying into a secular growth trend.
4. High barriers to entry. Starting a new Medicare-certified hospice from scratch requires a Certificate of Need (CON) in many states, a complex enrollment process, 12–18 months of operating history before meaningful census, and significant working capital. Acquiring an established agency is far cheaper and faster than building one — which creates structural premium for existing operators.
| Hospice Agency Profile | EBITDA Multiple Range |
|---|---|
| Small (<$500K EBITDA), single market | 4.5 – 6.0× |
| Mid-size ($500K – $2M EBITDA), established census | 5.5 – 7.5× |
| Large ($2M+ EBITDA), multi-county presence | 7.0 – 9.0× |
| Platform / multi-site ($5M+ EBITDA) | 8.0 – 11×+ |
Source: Irving Levin Associates 2025, Scope Research Q4 2025, Hendon Partners deal data
The wide range within each tier reflects the quality variables discussed below. Two hospice agencies with identical EBITDA can achieve materially different multiples depending on how they score on the drivers that matter most to buyers.
Average Daily Census is the single most scrutinized metric in any hospice acquisition. Buyers look at:
An ADC growing at 10%+ year-over-year commands a meaningful premium over a flat or declining census, even if the EBITDA is identical in the trailing twelve months. Buyers underwrite to future performance, and a growing census signals momentum.
ALOS in hospice is a proxy for clinical quality, referral relationships, and community trust. The national average ALOS is approximately 90 days. Agencies with ALOS above 90 days, particularly above 120 days, signal:
One important nuance: very high ALOS (180+ days) can trigger buyer concern about compliance risk, particularly around diagnosis appropriateness and recertification practices. Buyers will scrutinize your medical review processes.
In CON states, your geographic authorization to operate is a direct asset. Buyers are paying not just for your census and cash flow but for your right to serve specific counties. Multiple-county or multi-state operations with CON protection are worth materially more than a single-county license.
Even in non-CON states, your referral relationships — with physicians, hospitals, skilled nursing facilities, and assisted living communities — are geographically specific. Buyers assess whether those relationships can survive ownership transition.
The most common risk factor buyers identify in hospice due diligence is referral concentration. If more than 20–25% of your ADC comes from a single facility, physician group, or referral source, buyers will apply a discount. The concern is straightforward: if that relationship doesn’t transfer, the census — and therefore the value — evaporates.
Agencies with diversified referral networks across multiple facility types (SNF, ALF, hospital, community/home) consistently achieve better multiples.
While Medicare is the primary payer, buyers also look at:
A clean Medicare cost report history is non-negotiable for institutional buyers. Buyers will request 3–5 years of cost reports and will specifically look for:
If you have unresolved compliance issues, address them before going to market. Even allegations — not just findings — can derail a transaction or reduce pricing significantly.
“EBITDA” as reported on your tax return or P&L is rarely the number a buyer will use to value your business. A skilled M&A advisor will work through EBITDA normalization — adding back legitimate owner-benefit items and one-time expenses to arrive at the true recurring cash flow.
Common hospice add-backs:
| Item | Description |
|---|---|
| Owner compensation above market | If you pay yourself $400K but a replacement clinical director costs $150K, the $250K difference is an add-back |
| Personal expenses run through the business | Vehicle, travel, home office, personal insurance |
| One-time expenses | Legal fees for a resolved matter, a facility buildout not recurring, one-time IT migration |
| Startup costs | If you opened a new location in the past 12 months, its startup losses may be partially added back |
| Non-recurring revenue | If you received a one-time Medicare bonus or settlement, buyers may exclude it |
The difference between raw reported EBITDA and normalized EBITDA can be $200K–$500K for a well-run hospice — which translates to $1M–$4M in additional enterprise value at current multiples.
Understanding who will buy your agency is as important as understanding what it’s worth. The buyer landscape for hospice in 2026 includes:
Private Equity-Backed Platforms The most active buyers. These are PE-funded hospice companies using acquisition as their primary growth engine. They move quickly, pay competitive multiples, and often offer sellers rollover equity in the platform. Examples include Traditions Health, Compassus, VITAS, and dozens of regional platforms.
National Home-Based Care Companies Companies like Amedisys, LHC Group (now part of UnitedHealth), and Enhabit/Encompass are strategic acquirers when they want geographic fill-in. They tend to pay lower multiples than PE but offer more operational stability.
Regional Health Systems Hospital systems seeking to complete their continuum of care are sporadic but meaningful buyers. They typically pay more than financial buyers because they value the referral relationships strategically (not just financially).
Independent Hospice Operators Smaller operators seeking to scale within a specific geography. Typically pay the lowest multiples but can move faster and offer more cultural continuity.
In a well-run competitive M&A process, having all four buyer types at the table creates genuine competition — which is where premium multiples come from.
1. Selling to the first buyer who calls. Unsolicited buyers have already priced in the absence of competition. The first call is almost never the best offer.
2. Not having three years of clean financials. Missing or unorganized financials delay due diligence, increase buyer skepticism, and give sophisticated buyers leverage to renegotiate price downward.
3. Ignoring the hospice cap. If your agency is approaching the Medicare aggregate cap, buyers will discount heavily — or walk away. Monitor your cap position and manage census mix accordingly.
4. Waiting too long. Owners in their 60s who want to sell “in a few years” frequently encounter health challenges, key employee departures, or market shifts that reduce value. The best time to sell is when the business is strong.
5. Using a generalist broker. Hospice M&A is highly specialized. A generalist broker does not know the hospice-specific regulatory framework, the buyer universe, or how to present your census and compliance profile to maximize value.
The first step in any intelligent exit is getting an accurate picture of your baseline value — before you engage any buyer.
At Hendon Partners, our preliminary valuations for hospice agencies are free, confidential, and based on real deal data from closed transactions in the market. We’ll review your EBITDA, census profile, payor mix, and geography and give you a realistic range of what your agency would achieve in a competitive process.
Request your confidential hospice valuation →
Hendon Partners is a specialized M&A advisory firm exclusively focused on home-based care. Our team has represented owners of hospice, home health, private pay, and IDD agencies across the country. We do not represent buyers.
Newsletter
Receive new articles, EBITDA benchmark updates, and deal intelligence directly in your inbox. No spam — unsubscribe anytime.
Join 1,200+ home care executives. Unsubscribe anytime.
